Tatham: Lack of Ronapreve (REGN-CoV; casirivimab and imdevimab) virological efficacy against the SARS-CoV 2 Omicron variant (B.1.1.529) in K18-hACE2 mice [Casirivimab/imdevimab]

Lack of Ronapreve (REGN-CoV; casirivimab and imdevimab) virological efficacy against the SARS-CoV 2 Omicron variant (B.1.1.529) in K18-hACE2 mice

Tatham et al., bioRxiv, doi:10.1101/2022.01.23.477397 (Preprint)

Tatham et al., Lack of Ronapreve (REGN-CoV; casirivimab and imdevimab) virological efficacy against the SARS-CoV 2 Omicron.., bioRxiv, doi:10.1101/2022.01.23.477397 (Preprint)

Jan 2022 Source PDF

Twitter
Facebook

All Studies Meta

K18-hACE2 mouse study showing that casirivimab/imdevimab was not effective for omicron at doses 2x higher than those effective for previous variants.

Important missing comments or errors? Let us know.

Tatham et al., 24 Jan 2022, preprint, 15 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper Casirivimab/i..All

Lack of Ronapreve (REGN-CoV; casirivimab and imdevimab) virological efficacy against the SARS-CoV-2 Omicron variant (B.1.1.529) in K18-hACE2 mice

Lee Tatham, Joanne Sharp, Edyta Kijak, Joanne Herriott, Megan Neary, Helen Box, Anthony Valentijn, Helen Cox, Henry Pertinez, Paul Curley, Usman Arshad, Rajith Kr Rajoli, Steve Rannard, James Stewart, Andrew Owen

doi:10.1101/2022.01.23.477397

AO and SR are Directors of Tandem Nano Ltd and co-inventors of patents relating to drug delivery. AO has received research funding from ViiV, Merck, Janssen and consultancy from Gilead, ViiV and Merck not related to the current paper. SR has received research funding from ViiV and AstraZeneca and consultancy from Gilead not related to the current paper. No other conflicts are declared by the authors.

References

Ashraf, Altered sirtuin expression is associated with node-positive breast cancer, British Journal of Cancer, doi:10.1038/sj.bjc.6603384

Bentley, SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19

Chen, In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains, Nature, doi:10.1038/s41586-021-03720-y

Choudhary, Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy (Cold Spring Harbor Laboratory

Dejnirattisai, Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum, The Lancet, doi:10.1016/s0140-6736(21)02844-0

Dejnirattisai, leads to widespread escape from neutralizing antibody responses

Hiscox, Khoo, Stewart, Owen, Shutting the gate before the horse has bolted: is it time for a conversation about SARS-CoV-2 and antiviral drug resistance?, Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkab189

Horby, Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Ikemura, Engineered ACE2 counteracts vaccine-evading SARS-CoV-2 Omicron variant (Cold Spring Harbor Laboratory

Keeton, SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron

Lamontagne, A living WHO guideline on drugs to prevent covid-19, BMJ, doi:10.1136/bmj.n526

Medigeshi, Sub-optimal Neutralisation of Omicron

Neary, Evaluation of intranasal nafamostat or camostat for SARS-CoV-2 chemoprophylaxis in Syrian golden hamsters (Cold Spring Harbor Laboratory

O'brien, Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19

Peter Horby, Hiscox, Chand, Breuer, Sherwood et al., Antiviral drug resistance and the use of directly acting antiviral drugs (DAAs) for COVID-19

Redd, Minimal cross-over between mutations associated with Omicron variant of SARS-CoV-2 and CD8+ T cell epitopes identified in COVID-19 convalescent individuals

Rothenberger, a novel trispecific DARPin candidate that protects against SARS-CoV-2 variants (Cold Spring Harbor Laboratory

Ryan, Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity, Nature communications, doi:10.1038/s41467-020-20439-y

Salzer, Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice (Cold Spring Harbor Laboratory

Torjesen, Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear, BMJ, doi:10.1136/bmj.n2943

Vanblargan, An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies (Cold Spring Harbor Laboratory

Weinreich, REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19, New England Journal of Medicine, doi:10.1056/nejmoa2108163

Who, None

Wölfel, Virological assessment of hospitalized patients with COVID-2019, Nature, doi:10.1038/s41586-020-2196-x

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit